Hong Kong drug regulator chief vows trusted innovation hub
SCMP · 1 SOURCESabout 2 hours ago2 MIN
Summary
Hong Kong’s new medical products regulator is positioning itself as more than a local copy of established overseas agencies. Dr Li Zili, controller of the Hong Kong Centre for Medical Products Regulation, said the body should become a fully capable and globally trusted regulator that also acts as a catalyst for medical innovation. He said Hong Kong’s advantages lie in its “one country, two systems” framework and its proximity to mainland China’s pharmaceutical industry, which he described as increasingly important in global drug development
Key Points
- Dr Li Zili, head of the Hong Kong Centre for Medical Products Regulation, said the agency would not aim to be a “mini-FDA” or a smaller replica of any overseas regulator
- He said many Asian jurisdictions, including mainland China, Singapore and Japan, had established drug regulators long ago, but Hong Kong still had distinctive competitive strengths
- Li identified Hong Kong’s two main advantages as the “one country, two systems” principle and the mainland’s strong pharmaceutical industry
- He said 34 per cent of global innovative drug pipelines now came from mainland China, arguing that this showed clearly where Hong Kong’s strategic edge lay
- Li, educated at Beijing Union Medical College and Johns Hopkins University, was chosen after a global recruitment exercise that drew more than 20 applicants
Why It Matters
For Hong Kong, the regulator’s direction could shape whether the city becomes a meaningful gateway between mainland drug innovation and international standards, rather than remaining a secondary approval market. Li’s emphasis on trust and capability also suggests the government sees regulation not only as a safety function, but as part of a broader strategy to support biomedical development in the city